Interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Polymorphisms in the IL28B (interleukin-28B) gene region are important in predicting outcome following therapy for chronic hepatitis C virus (HCV) infection. The IL28B genotype test can be used to predict response to peg-IFN and RBV in HCV genotype 1 patients. The test result indicates whether the patient has an IL28B CC, CT, or TT genotype. Patients who have the IL28B CC genotype are more likely to have a SVR with peg-IFN and RBV treatment, whereas patients who have the TT genotype are more likely to be nonresponders. This information can help clinicians and patients make informed decisions on how to best manage their HCV infection.
No special preparation is needed for Interleukin 28b Genotype. Inform your doctor if you are on any medications or have any underlying medical conditions or allergies before undergoing Interleukin 28b Genotype. Your doctor depending on your condition will give specific instructions.
|UNISEX||All age groups||IL 28Bb CC genotype respond better than CT or TT genotypes|